EGFR and non-small cell lung carcinoma: In a phase 3 ADAURA trial including EGFR- mutated stage IB to IIIA NSCLC, adjuvant third-generation EGFR tyrosine-kinase inhibitor osimertinib increased two-year disease-free survival to 89%, compared to 52% in the placebo group (p < 0.001), in patients with tumors showing EGFR mutation [25].